Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective

Patients with classic Hodgkin lymphoma (cHL) that has relapsed after autologous or allogeneic transplant have limited treatment options and a poor prognosis. Immunotherapy with agents that target the PROGRAMMED DEATH 1 (PD-1) receptor have demonstrated clinical activity with durable responses in ear...

Descripción completa

Detalles Bibliográficos
Autores principales: Villasboas, Jose Caetano, Ansell, Stephen M., Witzig, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914357/
https://www.ncbi.nlm.nih.gov/pubmed/26848626
http://dx.doi.org/10.18632/oncotarget.7177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914357/
https://www.ncbi.nlm.nih.gov/pubmed/26848626
http://dx.doi.org/10.18632/oncotarget.7177

Ejemplares similares